obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406 Ångstroms; a solid state NMR spectrum comprising one or more or two or more or three ^{13}C chemical shifts selected from the group consisting of 213.4 ± 0.2, 171.8 ± 0.2, and 17.3 ± 0.2 ppm; and a solid state NMR spectrum comprising one or more or two ^{19}F chemical shifts selected from the group consisting of -118.9 ± 0.2 and -119.7 ppm ± 0.2.

10. The salt of any one of claims 1-9, wherein the salt is a substantially pure polymorph of S-camsylate polymorph Form A.

11. The salt of any one of claims 1-3, wherein the salt is a substantially pure polymorph of S-camsylate polymorph Form B or a substantially pure polymorph of S-camsylate polymorph Form C.

12. A pharmaceutical composition comprising the salt of any of claims 1-11.

~~13. A method of treating a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity, the method comprising administering to a mammal in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 12.~~

~~14. A method of treating cancer in a mammal, the method comprising administering to the mammal a therapeutically effective amount of the pharmaceutical composition of claim 12.~~

15. Use of a salt of any one of claims 1-11 in the manufacture for a medicament for the treatment of cancer.

obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406 Ångstroms; a solid state NMR spectrum comprising one or more or two or more or three ^{13}C chemical shifts selected from the group consisting of 213.4 ± 0.2, 171.8 ± 0.2, and 17.3 ± 0.2 ppm; and a solid state NMR spectrum comprising one or more or two ^{19}F chemical shifts selected from the group consisting of -118.9 ± 0.2 and -119.7 ppm ± 0.2.

10. The salt of any one of claims 1-9, wherein the salt is a substantially pure polymorph of S-camsylate polymorph Form A.

11. The salt of any one of claims 1-3, wherein the salt is a substantially pure polymorph of S-camsylate polymorph Form B or a substantially pure polymorph of S-camsylate polymorph Form C.

12. A pharmaceutical composition comprising the salt of any of claims 1-11.

13. Use of a therapeutically effective amount of the pharmaceutical composition of claim 12 for the manufacture of a medicament for the treatment of a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity.

14. Use of a therapeutically effective amount of the pharmaceutical composition of claim 12 for the manufacture of a medicament for the treatment of cancer.

15. Use of a salt of any one of claims 1-11 in the manufacture for a medicament for the treatment of cancer.